Report : Middle East & Africa Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)

At 6.1% CAGR, the Middle East & Africa Influenza Vaccines Market is speculated to be worth US$ 533.85 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa influenza vaccines market was valued at US$ 374.35 million in 2022 and is expected to reach US$ 533.85 million by 2028, registering an annual growth rate of 6.1% from 2022 to 2028. The emerging economies and strong pipeline candidates for influenza vaccines  are the critical factors attributed to the market expansion.

Leading players in the influenza vaccines market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting their manufacturing capabilities. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in upgrading the latest technologies in developing countries. In turn, this supports the inclination toward advanced vaccine development. Key producers of influenza vaccines is expected to witness lucrative opportunities in the near future due to the large patient pool and high prevalence of influenza, improving healthcare infrastructure, rising disposable income, and the surge of medical tourism in these countries.

On the contrary, high cost of vaccine development hurdles the growth of Middle East & Africa influenza vaccines market.

Based on vaccine type, the Middle East & Africa influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment held 90.3% market share in 2022, amassing US$ 338.19 million. It is projected to garner US$ 489.67 million by 2028 to expand at 6.4% CAGR during 2022–2028.

Based on virus type, the Middle East & Africa influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held 96.8% market share in 2022, amassing US$ 362.26 million. It is projected to garner US$ 519.40 million by 2028 to expand at 6.2% CAGR during 2022–2028.

Based on technology, the Middle East & Africa influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held 77.9% market share in 2022, amassing US$  291.46 million. It is projected to garner US$ 409.30 million by 2028 to expand at 5.8% CAGR during 2022–2028.

Based on route of administration, the Middle East & Africa influenza vaccines market is divided into injection and nasal spray. The injection segment held 73.3% market share in 2022, amassing US$  274.52 million. It is projected to garner US$ 399.18 million by 2028 to expand at 6.4% CAGR during 2022–2028.

 

 

Based on country, the Middle East & Africa influenza vaccines market is categorized into the UAE, Saudi Arabia, South Africa, and the rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 36.2% market share in 2022. It was assessed at US$ 135.40 million in 2022 and is likely to hit US$ 198.65 million by 2028, exhibiting a CAGR of 6.6% during the forecast period.

Key players dominating the Middle East & Africa influenza vaccines market are AstraZeneca; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure